<DOC>
	<DOCNO>NCT02675426</DOCNO>
	<brief_summary>This multi center , randomize , double-blind , placebo-controlled phase 3 study subject moderately severely active rheumatoid arthritis stable dose csDMARDs inadequate response csDMARDs .</brief_summary>
	<brief_title>A Study Comparing ABT-494 Placebo Subjects With Rheumatoid Arthritis Stable Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs ( csDMARDs ) Who Have Inadequate Response csDMARDs Alone</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult male female , least 18 year old . Diagnosis Rheumatoid Arthritis ( RA ) great equal 3 month . Subjects receive conventional synthetic DMARD ( csDMARD ) therapy great equal 3 month stable dose great equal 4 week prior first dose study drug . The following csDMARDs allow : Methotrexate ( MTX ) , sulfasalazine , hydroxychloroquine , chloroquine , leflunomide . Meets follow minimum disease activity criterion : great equal 6 swollen joint ( base 66 joint count ) great equal 6 tender joint ( base 68 joint count ) Screening Baseline Visits . Subjects prior exposure one biologic DMARD ( bDMARD ) may enrol ( 20 % study population ) document evidence intolerance bDMARDs limited exposure ( le 3 month ) satisfy require washout period . Prior exposure Janus kinase ( JAK ) inhibitor ( include limit tofacitinib , baricitinib , filgotinib ) . History inflammatory joint disease RA . History secondary Sjogren 's Syndrome permit . Subjects consider inadequate responder bDMARD therapy determine Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anti-inflammatory agent</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Musculoskeletal Disease</keyword>
	<keyword>Antirheumatic agent</keyword>
	<keyword>Arthritis</keyword>
</DOC>